GlassScriptPhysician profile
Timothy R Gilbert
NPI 1467568600
$984,503.14
in general payments reported to CMS, 2019-2025
60 companies · $71K in 2025
The $71K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251K · 2020: $145K · 2021: $203K · 2022: $139K · 2023: $82K · 2024: $93K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $75K · Travel and Lodging: $26K · Food and Beverage: $11K · Consulting Fee: $4,117 · Education: $12.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,166.29 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $75,260.00 |
| Travel and Lodging | $25,698.45 |
| Food and Beverage | $11,367.24 |
| Consulting Fee | $4,117.00 |
| Education | $12.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $339,295.34 | 2019-2023 | Farxiga, Lokelma |
| Novo Nordisk INC | $269,721.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $242,238.69 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $87,786.53 | 2019-2025 | |
| Insulet Corporation | $13,009.51 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,792.60 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $8,576.16 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Senseonics, Incorporated | $3,500.00 | 2019 | |
| Medtronic, INC. | $1,845.52 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $554.69 | 2019-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $368.44 | 2020-2023 | Nexletol |
| Abbvie INC. | $339.80 | 2019-2024 | |
| Kvk-Tech, INC. | $326.38 | 2019 | |
| Horizon Therapeutics Plc | $295.17 | 2021-2023 | Tepezza |
| Merck Sharp & Dohme LLC | $295.05 | 2019-2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $272.50 | 2020-2023 | Signifor Lar, Isturisa |
| Xeris Pharmaceuticals, INC. | $260.07 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $255.70 | 2019-2024 | Korlym |
| Antares Pharma, INC. | $244.32 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $205.86 | 2020-2025 | Tepezza, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $147.92 | 2022-2025 | |
| Averitas Pharma INC. | $136.68 | 2023-2024 | Qutenza |
| Grt US Holding, INC. | $134.65 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $126.43 | 2019-2022 | |
| Amarin Pharma, INC. | $126.10 | 2019-2021 | |
| Genentech, INC. | $120.19 | 2025 | |
| Eusa Pharma (US) LLC | $114.25 | 2022 | |
| Amryt Pharma Holdings LTD | $107.30 | 2020-2023 | Mycapssa, Myalept |
| Ultragenyx Pharmaceutical INC. | $106.86 | 2019-2022 | |
| Astellas Pharma US INC | $90.95 | 2023-2024 | Veozah |
| Shire North American Group INC | $88.70 | 2019 | |
| Tolmar, INC. | $81.73 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $80.16 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $71.03 | 2019-2023 | Strensiq |
| Mannkind Corporation | $59.40 | 2022 | |
| Madrigal Pharmaceuticals | $57.84 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $56.77 | 2019 | |
| Endo Pharmaceuticals INC. | $55.09 | 2019-2021 | |
| Medtronic Minimed, INC. | $47.47 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $47.29 | 2023-2025 | Imcivree, Imcivree |
| Vivus LLC | $45.89 | 2019-2020 | |
| Ibsa Pharma INC. | $38.68 | 2020 | |
| Kyowa Kirin, INC. | $37.15 | 2023-2024 | Crysvita |
| Acella Pharmaceuticals, LLC | $35.12 | 2025 | NP Thyroid 60 |
| Novartis Pharmaceuticals Corporation | $28.21 | 2022 | |
| Halozyme INC | $26.66 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $25.25 | 2023 | Somatuline Depot |
| Aytu Biopharma, INC. | $21.85 | 2019 | |
| Beta Bionics, INC. | $21.12 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $20.84 | 2024 | |
| Companion Medical, INC. | $20.35 | 2019 | |
| Nevro Corp. | $19.81 | 2022 | |
| Currax Pharmaceuticals LLC | $17.07 | 2025 | Contrave |
| Aegerion Pharmaceuticals, INC. | $16.33 | 2019 | |
| Clarus Therapeutics INC. | $15.56 | 2021 | |
| Radius Health, INC. | $15.50 | 2019 | |
| Pfizer INC. | $15.34 | 2021 | |
| Acerus Pharmaceuticals Corporation | $14.17 | 2022 | |
| Cequr Corporation | $13.99 | 2024 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.